machmit schreef op 21 oktober 2015 16:18:
Het aandeel Valeant mag dan wel dalen, maar heeft wel een opwaartse potentie aldus dit bericht van 21-10-15.
4 Analyst Stock Picks With 50% to 100% Upside Potentialat 24/7 Wall St.(Wed 8:35AM EDT)
Valeant Pharmaceuticals
This company took a headline beating for raising prices way too much. It is also a gigantic holding in Bill Ackman’s Pershing Square hedge fund. Valeant Pharmaceuticals International Inc. (NYSE: VRX) develops, manufactures and markets pharmaceuticals, over-the-counter products and medical devices worldwide. Its extensive list of products treat everything from severe acne to Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for cutaneous T-cell lymphoma; Arestin, a subgingival sustained-release antibiotic; and Provenge for the treatment of prostate cancer.Valeant shares are down a huge 37% in the past two months. The downtrend was particularly dramatic in September after a comment from presidential candidate Hillary Clinton on the rising prices of specialty drugs led to a massive sell-off in biotechs. The company responded this week by reporting solid third-quarter results, with revenues up a stunning 44% and earnings per share 36%. Ackman recently revealed Pershing Square’s big position in Valeant and said “If I had to pick one stock in our portfolio that is the most undervalued, it is Valeant.” While there always has been an eye raised at the company’s acquisition strategies from some corners of Wall Street, the upside potential is strong and Stifel agrees.
The Stifel price target is a gigantic $285, and the consensus target is $273. The stock closed Tuesday at $146.74, down almost 11%.